Cingulate Inc. announces the resignation of its General Counsel and Chief Financial Officer, as well as the departure of three directors. The company is implementing cost containment measures, including salary reductions and a review of vendors. Clinical trial plans have been paused pending FDA guidance. The company needs to raise significant capital to continue operations.